Evaluating head acupuncture after thrombectomy for stroke treatment
A Single-center, Prospective, Randomized, Controlled Study of Mechanical Thrombectomy Followed by Acupuncture for Acute Ischemic Stroke
This study is testing if adding head acupuncture to standard treatment after a stroke helps patients recover better than just the standard treatment alone.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 272 (estimated) |
| Ages | 18 Years to 100 Years |
| Sex | All |
| Sponsor | Xi'an No.3 Hospital Government |
| Locations | 1 site (Xi'an, Shaanxi) |
| Trial ID | NCT05561088 on ClinicalTrials.gov |
What this trial studies
This study aims to assess the efficacy and safety of head acupuncture when combined with endovascular therapy for patients suffering from acute ischemic stroke. Participants will be divided into two groups: one receiving mechanical thrombectomy followed by standard treatment, and the other receiving the same treatment plus head acupuncture. The goal is to determine if the addition of acupuncture enhances recovery outcomes compared to standard care alone.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older who have experienced an acute ischemic stroke and received endovascular treatment within 24 hours of onset.
Not a fit: Patients with confirmed intracranial tumors, hemorrhages, or those unable to cooperate due to mental illness or dementia may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could improve recovery rates and overall outcomes for patients who have suffered an acute ischemic stroke.
How similar studies have performed: While acupuncture has been explored in various contexts, this specific combination with mechanical thrombectomy is relatively novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥18 years; * Patients with acute ischemic stroke who received endovascular treatment within 24 hours of onset; * 6 \< NIHSS ≤25; * ASPECT score ≥6 points; * Signed Informed consent. Exclusion Criteria: * CT or brain MRI confirmed intracranial tumor and intracranial hemorrhage; * Contraindications of contrast media; * Dementia or mental illness，unable to cooperate with treatment and follow-up; * The expected survival time was less than 3 months; * Women who are pregnant, planning to become pregnant or breastfeeding; * Currently participating in other clinical trials.
Where this trial is running
Xi'an, Shaanxi
- Xi 'an No.3 Hospital — Xi'an, Shaanxi, China (Recruiting)
Study contacts
- Study coordinator: Shilin L i, Doctor
- Email: lihuashiling@126.com
- Phone: 8615398076154
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.